A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. [electronic resource]
Producer: 20121025Description: 1210-7 p. digitalISSN:- 1528-0020
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antibodies, Monoclonal, Murine-Derived -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Bevacizumab
- Cyclophosphamide -- administration & dosage
- Dose-Response Relationship, Drug
- Doxorubicin -- administration & dosage
- Female
- Humans
- Lymphoma, Large B-Cell, Diffuse -- diagnosis
- Male
- Middle Aged
- Neoadjuvant Therapy
- Prednisone -- administration & dosage
- Rituximab
- Standard of Care
- Survival Analysis
- Treatment Outcome
- Vincristine -- administration & dosage
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.